Everolimus Patent Expiration
Everolimus is used for treating advanced hormone receptor positive, HER2-negative breast cancer, progressive neuroendocrine tumors of pancreatic origin, tuberous sclerosis complex with subependymal giant cell astrocytoma, and solid excretory system tumors including advanced renal cell carcinoma. It was first introduced by Novartis Pharmaceuticals Corp
Everolimus Patents
Given below is the list of patents protecting Everolimus, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Afinitor | US9006224 | Neuroendocrine tumor treatment | Jul 01, 2028 | Novartis |
| Afinitor |
US8410131 (Pediatric) | Cancer treatment |
May 01, 2026
(Expired) | Novartis |
| Afinitor | US8410131 | Cancer treatment |
Nov 01, 2025
(Expired) | Novartis |
| Afinitor Disperz |
US8617598 (Pediatric) | Pharmaceutical compositions comprising colloidal silicon dioxide |
Mar 27, 2023
(Expired) | Novartis Pharm |
| Afinitor Disperz | US8617598 | Pharmaceutical compositions comprising colloidal silicon dioxide |
Sep 27, 2022
(Expired) | Novartis Pharm |
| Afinitor |
US8436010 (Pediatric) | Treatment of solid tumors with rapamycin derivatives |
Aug 22, 2022
(Expired) | Novartis |
| Afinitor |
US8778962 (Pediatric) | Treatment of solid tumors with rapamycin derivatives |
Aug 18, 2022
(Expired) | Novartis |
| Afinitor Disperz |
US8778962 (Pediatric) | Treatment of solid tumors with rapamycin derivatives |
Aug 18, 2022
(Expired) | Novartis Pharm |
| Afinitor | US8436010 | Treatment of solid tumors with rapamycin derivatives |
Feb 22, 2022
(Expired) | Novartis |
| Afinitor | US8778962 | Treatment of solid tumors with rapamycin derivatives |
Feb 18, 2022
(Expired) | Novartis |
| Afinitor Disperz | US8778962 | Treatment of solid tumors with rapamycin derivatives |
Feb 18, 2022
(Expired) | Novartis Pharm |
| Afinitor |
US7297703 (Pediatric) | Macrolides |
Jun 06, 2020
(Expired) | Novartis |
| Afinitor Disperz |
US7297703 (Pediatric) | Macrolides |
Jun 06, 2020
(Expired) | Novartis Pharm |
| Afinitor |
US5665772 (Pediatric) | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
Mar 09, 2020
(Expired) | Novartis |
| Afinitor Disperz |
US5665772 (Pediatric) | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
Mar 09, 2020
(Expired) | Novartis Pharm |
| Zortress |
US5665772 (Pediatric) | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
Mar 09, 2020
(Expired) | Novartis |
| Afinitor | US7297703 | Macrolides |
Dec 06, 2019
(Expired) | Novartis |
| Afinitor | US7741338 | Macrolides |
Dec 06, 2019
(Expired) | Novartis |
| Afinitor Disperz | US7297703 | Macrolides |
Dec 06, 2019
(Expired) | Novartis Pharm |
| Afinitor | US5665772 | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
Sep 09, 2019
(Expired) | Novartis |
| Afinitor Disperz | US5665772 | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
Sep 09, 2019
(Expired) | Novartis Pharm |
| Zortress | US5665772 | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
Sep 09, 2019
(Expired) | Novartis |
| Zortress |
US6239124 (Pediatric) | Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin |
Feb 11, 2018
(Expired) | Novartis |
| Zortress |
US6455518 (Pediatric) | Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-O-(2-hydroxyethyl)-rapamycin |
Jan 29, 2018
(Expired) | Novartis |
| Zortress | US6239124 | Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin |
Aug 11, 2017
(Expired) | Novartis |
| Zortress | US6455518 | Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-O-(2-hydroxyethyl)-rapamycin |
Jul 29, 2017
(Expired) | Novartis |
| Afinitor |
US6004973 (Pediatric) | Pharmaceutical compositions comprising rafamycin coprecipitates |
Jan 12, 2017
(Expired) | Novartis |
| Afinitor Disperz |
US6004973 (Pediatric) | Pharmaceutical compositions comprising rafamycin coprecipitates |
Jan 12, 2017
(Expired) | Novartis Pharm |
| Zortress |
US6004973 (Pediatric) | Pharmaceutical compositions comprising rafamycin coprecipitates |
Jan 12, 2017
(Expired) | Novartis |
| Afinitor | US6004973 | Pharmaceutical compositions comprising rafamycin coprecipitates |
Jul 12, 2016
(Expired) | Novartis |
| Afinitor Disperz | US6004973 | Pharmaceutical compositions comprising rafamycin coprecipitates |
Jul 12, 2016
(Expired) | Novartis Pharm |
| Zortress | US6004973 | Pharmaceutical compositions comprising rafamycin coprecipitates |
Jul 12, 2016
(Expired) | Novartis |
| Zortress |
US6440990 (Pediatric) | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
Mar 24, 2014
(Expired) | Novartis |
| Zortress | US6440990 | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
Sep 24, 2013
(Expired) | Novartis |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Everolimus's patents.
Latest Legal Activities on Everolimus's Patents
Given below is the list recent legal activities going on the following patents of Everolimus.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Post Issue Communication - Certificate of Correction | 10 Nov, 2018 | US6455518(Litigated) |
| Post Issue Communication - Certificate of Correction | 10 Sep, 2018 | US6455518(Litigated) |
| Post Issue Communication - Certificate of Correction | 21 Jun, 2018 | US6455518(Litigated) |
| Post Issue Communication - Certificate of Correction | 14 May, 2018 | US6455518(Litigated) |
| Mail Certificate of Correction Memo | 18 Apr, 2018 | US6455518(Litigated) |
| Certificate of Correction Memo | 17 Apr, 2018 | US6455518(Litigated) |
| Request for Trial Denied Critical
| 28 Apr, 2016 | US6455518(Litigated) |
| Petition Requesting Trial | 26 Oct, 2015 | US6455518(Litigated) |
| Patent Issue Date Used in PTA Calculation Critical
| 24 Sep, 2002 | US6455518(Litigated) |
| Recordation of Patent Grant Mailed Critical
| 24 Sep, 2002 | US6455518(Litigated) |
Everolimus's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Everolimus:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
